A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
|ClinicalTrials.gov Identifier: NCT01614665|
Recruitment Status : Active, not recruiting
First Posted : June 8, 2012
Last Update Posted : December 21, 2017
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and effective they are over a longer period of time.
This study is for children less than 16 years old. No minimum age has been set, however, to be included in this study participants must able to swallow the medication capsules intact.
|Condition or disease||Intervention/treatment||Phase|
|Heart Transplantation Kidney Transplantation Liver Transplantation||Drug: Tacrolimus||Phase 2|
Subjects undergoing primary heart, kidney or liver transplantation and meeting the Inclusion Criteria and complying with the Exclusion Criteria prior to initiation of tacrolimus therapy will be enrolled.
Subjects will be randomized to treatment with either Advagraf® or Prograf®. The randomization will be on a 1:1 basis stratified by organ and centre.
The study is divided in to two parts:
Part A: The initial pharmacokinetic part of the study.
Part B: A long term follow-up of one year. The main objective of Part A of the study is to collect PK data following administration of Advagraf® and Prograf® in de novo pediatric allograft recipients. Part B allows comparison of the safety and efficacy profiles of Advagraf® vs. Prograf® for longer term (52 weeks) post allograft transplantation.
Part C: Continuation of long-term follow-up (from Day 365 onwards). Patients who have completed Part B and to whom continued treatment with Advagraf® is not currently available, will be offered participation in a continuation of long-term follow-up Part C. Part C will continue until Advagraf® becomes available to these patients or these patients' discontinuation, whichever is the earliest.
This applies to patients in the following countries: Czech Republic, Italy, UK and Poland only.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated With an Advagraf® or Prograf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up|
|Actual Study Start Date :||April 3, 2012|
|Estimated Primary Completion Date :||May 2026|
|Estimated Study Completion Date :||May 2026|
Active Comparator: Prograf®
- Part A: Determine steady state systemic exposure (AUC0-24h) [ Time Frame: Day 1, Day 7 and Day 28 ]
- Part A & B: Assessment of safety through the evaluation of adverse events, laboratory parameters and vital signs [ Time Frame: Up to 1 year ]
- Part C: Assessment of safety through evaluation of adverse events [ Time Frame: Up to 9 years ]
- Part A: Determine Cmax (maximum concentration) [ Time Frame: Day 1, Day 7 and Day 28 ]
- Part A: Determine Tmax (time to attain Cmax) [ Time Frame: Day 1, Day 7 and Day 28 ]
- Part A: Determine C24 (concentration prior to morning dose) [ Time Frame: Day 1, Day 7 and Day 28 ]
- Part A & B: Rejection episodes [ Time Frame: Up to 1 year (End of study) ]
- Part A & B: Subject and graft survival [ Time Frame: Up to 1 year (End of study) ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01614665
|Prague 5, Czechia, 150 06|
|Bron Cedex, France, 69677|
|Paris Cedex 15, France|
|Rome, Italy, 00165|
|Warsaw, Poland, 04-730|
|Birmingham, United Kingdom, B4 6NH|
|Liverpool, United Kingdom, L12 2AP|
|London, United Kingdom, SE5 9RS|
|London, United Kingdom, WC1 3JH|
|Manchester, United Kingdom, M13 9WL|
|Study Director:||Clinical Study Manager||Astellas Pharma Europe Ltd.|